Isolated Elevated Lp(a)
An elevated lipoprotein(a) concentration is a genetically determined cardiovascular risk enhancer and should be incorporated into overall ASCVD risk assessment, even when the routine lipid profile is otherwise favorable.
Risk context
An elevated lipoprotein(a) concentration represents a genetically determined cardiovascular risk enhancer and should be incorporated into the overall assessment of future atherosclerotic cardiovascular disease risk, even when the conventional lipid profile is otherwise favorable.
Although the current LDL cholesterol level may already meet the customary target of less than 100 mg/dL for primary prevention of clinical ASCVD, discussion regarding initiation of statin therapy may still be appropriate in the context of elevated Lp(a), after consideration of the patient’s overall cardiovascular risk profile, preferences, and anticipated benefit.
Shared decision-making
Shared decision-making may be facilitated through use of a validated cardiovascular risk estimator, such as the American Heart Association PREVENT™ Calculator, together with individualized review of additional clinical risk factors.
When uncertainty remains regarding the intensity of preventive therapy, coronary artery calcium scoring may provide additional information regarding the presence of subclinical coronary atherosclerosis and may help refine treatment decisions.
Comprehensive risk reduction
Elevated Lp(a) should be considered alongside all other cardiovascular risk modifiers when determining the need for more intensive preventive strategies.
Comprehensive management includes optimization of blood pressure, lipid parameters, glycemic control when applicable, body weight, physical activity, nutrition, tobacco avoidance, and other modifiable cardiovascular risk factors.
Evidence of coronary calcification, subclinical atherosclerosis, or an otherwise elevated estimated ASCVD risk may support pursuing more intensive LDL cholesterol reduction despite an LDL concentration that would otherwise be considered acceptable.
Cascade screening
Because lipoprotein(a) levels are largely inherited, cascade screening of biologically related first-degree relatives, including parents, siblings, and children who have not previously undergone testing, may be appropriate.
Family-based evaluation is particularly valuable when there is a history of premature ASCVD, early calcific aortic valve disease, or familial hypercholesterolemia, as identification of additional affected relatives may permit earlier implementation of preventive cardiovascular care.